Related Experiment Video
Updated: May 31, 2026
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Analytical Validation of Short-Read Genome Sequencing for Diagnostic Panel and Exome Testing
Yao Yang1, Nathan A Hammond2, Pun Wai Tong2
1Department of Pathology, Stanford University, Stanford, California; Clinical Genomics Laboratory, Stanford Medicine, Palo Alto, California.
Short-read genome sequencing demonstrates high accuracy and robustness for detecting genetic variants like single nucleotide variants (SNVs), insertions/deletions (indels), and copy number variants (CNVs). This validation supports its clinical use for diagnostic genome-based panels and exome testing.
Area of Science:
- Genomics
- Clinical Diagnostics
- Bioinformatics
Background:
- Clinical genetic disease research commonly uses genome sequencing.
- Most clinical labs use targeted sequencing for panels and exome testing.
- Short-read genome sequencing requires analytical validation for clinical implementation.
Purpose of the Study:
- Validate short-read genome sequencing (≥40X) for clinical diagnostic panels.
- Assess accuracy and reproducibility for SNVs, indels, and CNVs.
- Evaluate performance across different specimen types (blood, saliva).
Main Methods:
- Analytical validation of short-read genome sequencing (≥40X).
- Assessed SNV, indel, and CNV accuracy, reproducibility, and repeatability.
- Used GIAB/NIST reference materials and control specimens.
- Evaluated contamination thresholds and mosaicism detection.
Main Results:
- SNV/indel accuracy and precision >99.9% in non-difficult regions.
- CNV detection sensitivity, specificity, and accuracy >99.9% for deletions and duplications.
- High genotype concordance for SNVs/indels (>99%) and CNVs (>97% deletions, >81% duplications).
- Maintained >99% SNV/indel accuracy up to ~9% contamination and detected ~30% mosaicism.
Conclusions:
- Short-read genome sequencing (≥40X) is highly accurate and robust for germline SNV/indel and CNV detection.
- The validated platform supports its use for diagnostic genome-based panel and exome testing.
- This facilitates the implementation of clinical genome-based testing.
